J&J close to Risperdal settlement with DoJ: WSJ

SAN FRANCISCO (MarketWatch)
Johnson & Johnson Inc. and the Justice Department are close to settling allegations e company improperly marketed its antipsychotic medication Risperdal, The Wall Street Journal reported in its online edition late Wednesday, citing people close to the matter
The settlement is expected to be one of the largest for a drug-marketing case
J&J and the government are discussing a deal between $1.5 billion and $1.7 billion, though the final amount may top $2 billion to satisfy state prosecutors, according to the Journal